Showing results (211-220 of 232) with videos related to

Sort By:
Pageof 24
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 8, 2025
Metabolic and vascular contributions to dementia: Soluble epoxide hydrolase-derived linoleic acid oxylipins and glycemic status are related to cerebral small vessel disease markers, atrophy, and cognitive performanceSi Won Ryoo, William Z Lin, Alexandra Magliocco, et al.
NPJ Vaccines|August 27, 2024
Neutralizing and binding antibody responses to SARS-CoV-2 with hybrid immunity in pregnancyLin Li, Yusuke Matsui, Mary K Prahl, et al.
Scientific Reports|July 3, 2024
NF-κB inhibitor alpha controls SARS-CoV-2 infection in ACE2-overexpressing human airway organoidsCamille R Simoneau, Pei-Yi Chen, Galen K Xing, et al.
The Journal of Hospital Infection|June 12, 2023
Evaluating the cost implications of integrating SARS-CoV-2 genome sequencing for infection prevention and control investigation of nosocomial transmission within hospitalsM Panca, J Blackstone, O Stirrup, et al.
Plos Pathogens|March 31, 2025
Enhanced RNA replication and pathogenesis in recent SARS-CoV-2 variants harboring the L260F mutation in NSP6Taha Y Taha, Shahrzad Ezzatpour, Jennifer M Hayashi, et al.
Leukemia|February 18, 2021
Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myelomaArantxa Carrasco-Leon, Teresa Ezponda, Cem Meydan, et al.
Emerging Microbes & Infections|October 23, 2023
Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccinationRahul K Suryawanshi, Taha Y Taha, Maria McCavitt-Malvido, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
Journal of Medicinal Chemistry|January 6, 2026
Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection ModelsLuca Lizzadro, Jiapeng Li, Taha Y Taha, et al.
Elife|November 19, 2025
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2Rahul K Suryawanshi, Priyadarshini Jaishankar, Galen J Correy, et al.
Pageof 24